Reaktionsgleichung
[Cl:1][C:2]1[C:11]2[C:10]([S:12](Cl)(=[O:14])=[O:13])=[CH:9][CH:8]=[CH:7][C:6]=2[CH:5]=[N:4][CH:3]=1.[C:16]([O:20][C:21]([NH:23][C@H:24]1[CH2:29][CH2:28][CH2:27][NH:26][CH2:25]1)=[O:22])([CH3:19])([CH3:18])[CH3:17]>>[C:16]([O:20][C:21]([NH:23][C@H:24]1[CH2:29][CH2:28][CH2:27][N:26]([S:12]([C:10]2[C:11]3[C:2]([Cl:1])=[CH:3][N:4]=[CH:5][C:6]=3[CH:7]=[CH:8][CH:9]=2)(=[O:14])=[O:13])[CH2:25]1)=[O:22])([CH3:19])([CH3:17])[CH3:18].[NH2:23][C@H:24]1[CH2:29][CH2:28][CH2:27][N:26]([S:12]([C:10]2[C:11]3[C:2]([Cl:1])=[CH:3][N:4]=[CH:5][C:6]=3[CH:7]=[CH:8][CH:9]=2)(=[O:14])=[O:13])[CH2:25]1.[ClH:1]Komponenten
5
Versuchsvorschrift
(S)-3-(tert-Butoxycarbonylamino)-1-(4-chloro-5-isoquinolinesulfonyl)-piperidine (Intermediate 18a) was prepared from 4-chloro-5-isoquinolinesulfonyl chloride (183 mg) and (S)-3-(tert-butoxycarbonylamino)piperidine (168 mg) according to the method described in Example 1-1, Step A, and then used in the method of Example 1-1, Step B in a similar manner to obtain the title compound as hydrochloride (164 mg).
Quellen und Nachweise
- ORD-Eintrag
- ord-66e2bd0e5d04453c84eade2bb4c82cdb
- Quelldatensatz
- uspto-grants-2013_04
- Patentnummer
- US08415372B2
Verknüpfte Notizen
Wird geladen…